RE:RE:Lung cancer - Univ. of Washington ...LS29 ... The time has not come yet to do a global partnership simply because TLT/UHN know what they have in their hands.
They decided to go all alone till Ph. 2b daata a long time ago, even before they first treated p#1 of Ph. 1b, based on scientific data and what they saw and what you don't know. I'll take UHN as an adviser before you.
It's not about how long you've been in the stock. It's about them knowing what upper hand they can have against big pharmas when the real negociations begin once they have 3m and 1y Ph. 2b on a larger pool of patients that correspond to what FDA has set as endpoint.
Univ. of Washington looks desperate. They can only obtain peanuts compared to what we are in a position to obtain upon Ph. 2b data.
Do you really believe that U of W would have the upper hand by signing that early, compared to TLT if TLT shows clear Ph. 2b data? You know the value of upfront payment for pre-clinical data versus Ph. 1b data and Ph. 2b? Not to mention royalty rates.
TLD-1433 is the most advanced oncology drug that UHN ever had to investigate.
Out time will come when Ph. 2b data gradually comes out.